Skip to content
HowShorted

Axsome Therapeutics, Inc. short interest in 2019

In 2019, Axsome Therapeutics, Inc.'s disclosed short interest ran from 6.05% of shares outstanding on 15 Jan 2019 to 14.58% on 31 Dec 2019, a change of +8.53 percentage points. The year's high was 18.71% on 15 Jul 2019 and its low 6.05% on 15 Jan 2019, averaging 15.18% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.81 days on 30 Aug 2019. Full history: Axsome Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Axsome Therapeutics, Inc. in 2019

2019 in figures

Start of year
6.05% (15 Jan 2019)
End of year
14.58% (31 Dec 2019)
Change
+8.53 pp
High
18.71% (15 Jul 2019)
Low
6.05% (15 Jan 2019)
Average
15.18%
Highest days to cover
12.81 (30 Aug 2019)
SEC filings marked
8

Every report in 2019

Axsome Therapeutics, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 20196.05%1.00
31 Jan 20196.93%2.26
15 Feb 20199.65%2.90
28 Feb 20199.74%4.85
15 Mar 201911.54%3.87results (8-K), 10-K filed
29 Mar 201915.31%2.15
15 Apr 201915.84%5.57
30 Apr 201915.10%4.09
15 May 201917.07%4.1110-Q filed, results (8-K)
31 May 201918.56%4.25
14 Jun 201917.23%5.47
28 Jun 201917.70%3.69
15 Jul 201918.71%6.58
31 Jul 201917.77%7.38
15 Aug 201917.59%7.7810-Q filed, results (8-K)
30 Aug 201917.20%12.81
13 Sep 201916.29%11.05
30 Sep 201916.24%6.87
15 Oct 201917.74%3.66
31 Oct 201917.07%7.08
15 Nov 201917.28%7.7210-Q filed, results (8-K)
29 Nov 201917.66%5.06
13 Dec 201915.51%4.10
31 Dec 201914.58%1.84

See also: Axsome Therapeutics, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.